Aster DM Healthcare Q4 FY26 Earnings Call Transcript Released
Aster DM Healthcare released its Q4 FY26 earnings call transcript. The combined proforma revenue grew 18% to ₹2,361 crore, with EBITDA up 25% to ₹517 crore. Full-year combined revenue reached ₹9,273 crore, up 14%, and EBITDA ₹2,013 crore, up 21%. The merger with Quality Care is nearing completion. Aster's standalone Q4 FY26 revenue grew 18% to ₹1,182 crore, with EBITDA up 26% to ₹244 crore.
The transcript provides detailed financial results and updates on the merger with Quality Care, which are material information for investors. The information shared can influence investment decisions and is therefore of medium impact.
The announcement is a transcript of an earnings call, which provides detailed financial and operational updates. While the results discussed are generally positive, the transcript itself is a factual disclosure and does not inherently carry a positive or negative sentiment.
Aster DM Healthcare Limited has released the transcript of its earnings conference call for the quarter and year ended March 31, 2026. The call, held on May 1, 2026, featured management including Ms. Alisha Moopen (Deputy Managing Director), Mr. T J Wilson (Non-Executive Director), Mr. Ramesh Kumar (Chief Operating Officer), Mr. Sunil Kumar (Chief Financial Officer), and Mr. Hitesh Dhaddha (Chief Investor Relations & M&A Officer). Mr. Varun Khanna, Group MD & CEO of QCIL, also provided insights into QCIL's business and future plans, as QCIL is in the process of merging with Aster DM Healthcare, subject to regulatory approvals.
During the call, Ms. Alisha Moopen highlighted the combined proforma performance of Aster and Quality Care, with revenues growing 18% year-on-year to ₹2,361 crore for the quarter, supported by a 12% increase in total patient volumes and an 8% improvement in ARPP IP. Operating EBITDA grew by 25% to ₹517 crore, with margins at 21.9% and ROCE improving by 293 basis points to 21.1%. For the full year FY26, the combined platform delivered revenue of ₹9,273 crore, a 14% year-on-year increase, with Operating EBITDA growing 21% to ₹2,013 crore and margins expanding to 21.7%. The company also provided an update on its capacity expansion, adding 373 beds in the past year to reach over 10,620 beds, with a pipeline of 4,445 additional beds.
The merger with Quality Care is progressing, with shareholder and creditor approvals received, and the application filed with the NCLT on December 11, 2025. The next hearing is expected in May, with completion anticipated within the current quarter. Aster's standalone performance for Q4 FY26 showed revenue growth of 18% to ₹1,182 crore, with Operating EBITDA at ₹244 crore, a 26% increase, and margins at 20.7%. The company also highlighted strong performance in its core hospitals and clinics, with Operating EBITDA growing 32% and margins at 23.1%. Recognition was also received for its hospitals and leadership in various rankings and awards.
QCIL reported Q4 FY26 revenue growth of 18% year-on-year to ₹1,178 crore, with EBITDA growing 23% to ₹272 crore and margins expanding to 23.1%. For the full year, QCIL registered a 17% revenue growth to ₹4,630 crore and EBITDA of ₹1,066 crore, a 24.1% increase, with EBITDA margins at 23.0%. QCIL also announced plans to invest approximately ₹2,000 crore to add over 1,700 beds in the next 3-4 years, with a significant portion in non-metro markets.
What to do with a filing like this
Aster DM Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aster DM Healthcare Limited. Read the original for the full detail.